Today marks the launch of Patent Enforcement in the UK and Trans-Pacific Countries, an essential guide for private practitioners, in-house lawyers and other professionals with responsibility for intellectual property who are interested in the Trans-Pacific region.
Published by Globe Law and Business, the guide features contributions by Taylor Wessing experts Paul England, Amanda Ebbutt and Tom Foster, as well as a number of leading patent lawyers from Australia, Canada, US, Japan, South Korea, Singapore and New Zealand.
Paul England, senior professional support lawyer and the guide's…
We have helped secure the sale of the private healthcare company behind London's Parkside and Highgate hospitals.
The deal saw Aspen Healthcare, which runs eight hospitals and clinics around the UK, sold to NorthWest Healthcare Properties Real Estate Investment Trust.
The Canadian-based healthcare property trust took over in August this year, but it already owned some of the sites leased by Aspen Healthcare.
Our team worked with specialist insurance broker Howdens to help arrange a "synthetic" warranty and indemnity, and tax deed insurance package for the buyer.
This is one of…
New research reveals the confidence and capability of business in addressing international trade concerns.
In-Brief:
What are trade teams being asked to support and how confident do they feel in meeting business needs?
To deliver long-term value, what practical steps are needed to move from just the ‘basics’ to best in class?
How do UK companies differ from their global peers and how do they define their trade strategy?
Edinburgh and Cambridge, UK, 1 October 2021 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made five new appointments to its scientific team, to support and accelerate its R&D. Moritz Haneklaus PhD joins as Senior Scientist, Carmen Rodriguez Seoane PhD as Scientist, with Chantell Payton PhD and Conor Poland PhD joining as Associate Scientists, and Sadie Kemp BSc as Senior Research Technician. Moritz will be based in Cambridge and will utilise his deep immunology expertise to support progression of the company…
Click here to view the September edition of Dates for Your Diary
Click here to read the full edition of the September 2021 People Pathways newsletter.
A Newcastle biotech, specialising in nanorobotic technology to improve the diagnosis of some of the world’s most serious diseases, has joined Newcastle Helix.
Nanovery, a biotechnology company formed in 2018, are developing nanorobots for a quick and easy test to help in the diagnosis of cancer and other diseases. The test is based on DNA nanotechnology and costs less than tissue biopsy, whilst reducing risk to patients.
The company, formed in London, moved to Newcastle in 2020, to collaborate and access some of the city’s most renowned academics and partners in the field of research and…
CAMBRIDGE, UK and NEW YORK, USA, 28 September 2021: Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA Damage Response process in order to treat patients suffering from a broad range of cancers, announces it has dosed the first patient in its Phase 1/2a study with its polymerase theta (Polθ) inhibitor, ART4215. The Polθ project was originally in-licensed from Cancer Research UK in 2016 as part of the initial formation of Artios.
The open label, multi-center study will assess the safety, tolerability,…
Babraham, 27 September 2021: Five promising early-stage life science ventures are beginning the next steps of their entrepreneurial adventure at one of the most successful locations for life science start-ups in Europe, the Babraham Research Campus, CambridgeNow in its fourth year, Accelerate@Babraham, the bio-entrepreneurial incubator initiative established and developed by the Babraham Research Campus, has announced its 2021/22 winning cohort who begin their five-month journey today with a week-long life sciences bootcamp.The winning ventures will be able to…
We have advised Shore Capital (Nominated Adviser, Joint Broker and Joint Bookrunner) and Stifel (Joint Broker & Joint Bookrunner) on a $354 million (£265.5 million) placing and retail offer for Kape Technologies plc, a leading B2C privacy-first digital security software provider.
The capital raise was structured as an accelerated bookbuild placing, and was supported by new and existing institutional shareholders, including a number of blue-chip institutional investors from the UK, USA, Israel and Asia. The proceeds of the raise will be used to fund the upfront consideration for the…